Assessment of ARIA Sufficiency: Uplizna (inebilizumab-cdon) Read more about Uplizna (inebilizumab-cdon)
Characterization of COVID-19 Vaccinations: A Descriptive Analysis Read more about Characterization of COVID-19 Vaccinations: A Descriptive Analysis
Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis" Read more about Severe COVID-19 Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis"
COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis" Read more about COVID-19 Hospitalization Algorithm Defined in "COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis"
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis Read more about COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis
Use Case 2 (UC2) Aim 2: Empirical Application of Linked Dev Network (Y5): Correcting Claims Analyses for Unmeasured Confounding Using Subset Calibration Tools Read more about Use Case 2 (UC2) Aim 2: Empirical Application of Linked Dev Network (Y5): Correcting Claims Analyses for Unmeasured Confounding Using Subset Calibration Tools
Characterization of Most Frequent Diagnoses, Procedures, Medications and Labs Associated with Use of Finerenone in TriNetX: A Descriptive Analysis Read more about Characterization of Most Frequent Diagnoses, Procedures, Medications and Labs Associated with Use of Finerenone in TriNetX: A Descriptive Analysis